Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Current Deferred Revenue (2016 - 2026)

Champions Oncology has reported Current Deferred Revenue over the past 16 years, most recently at $10.0 million for Q1 2026.

  • Quarterly results put Current Deferred Revenue at $10.0 million for Q1 2026, down 8.46% from a year ago — trailing twelve months through Jan 2026 was $10.0 million (down 8.46% YoY), and the annual figure for FY2025 was $15.4 million, up 27.69%.
  • Current Deferred Revenue for Q1 2026 was $10.0 million at Champions Oncology, down from $12.3 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CSBR hit a ceiling of $15.4 million in Q2 2025 and a floor of $8.7 million in Q1 2022.
  • Median Current Deferred Revenue over the past 5 years was $11.2 million (2022), compared with a mean of $11.8 million.
  • Biggest five-year swings in Current Deferred Revenue: soared 98.87% in 2022 and later fell 21.38% in 2024.
  • Champions Oncology's Current Deferred Revenue stood at $11.2 million in 2022, then grew by 16.07% to $13.0 million in 2023, then dropped by 21.38% to $10.2 million in 2024, then increased by 20.72% to $12.3 million in 2025, then fell by 18.97% to $10.0 million in 2026.
  • The last three reported values for Current Deferred Revenue were $10.0 million (Q1 2026), $12.3 million (Q4 2025), and $14.4 million (Q3 2025) per Business Quant data.